Diagnosis and management of von Willebrand disease

A. B. Federici, P. M. Mannucci

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

von Willebrand disease (vWD) is a bleeding disorder caused by quantitative or qualitative defects of von Willebrand factor (vWF). The diagnosis is based on measurements of plasma and platelet vWF, the ability of vWF to interact with its platelet receptor and the analysis of the mutlimeric composition of vWF. Due to the heterogeneity of vWF defects, a correct diagnosis of types and subtypes may be sometimes difficult but is very important for an appropriate therapy. The aim of treatment is to correct the dual defects of haemostasis, i.e. abnormal coagulation expressed by low levels of factor VIII (FVIII) and abnormal platelet adhesion expressed by a prolonged bleeding time (BT). Desmopressin is the treatment of choice in patients with type 1 vWD, who account for approximately 80% of cases, because it corrects the FVIII/vWF levels and the prolonged BT in most of these patients. In type 3 and in the majority of type 2 vWD patients, desmopressin is not effective and it is necessary to resort to plasma concentrates containing FVIII and vWF. Treated with virucidal methods, these concentrates are effective and currently safe, but the BT defect is not always corrected by them. Platelet concentrates or desmopressin can be used as adjunctive treatments when poor correction of the BT after concentrates is associated with continued bleeding.

Original languageEnglish
Pages (from-to)28-37
Number of pages10
JournalHaemophilia
Volume5
Issue numberSUPPL. 2
Publication statusPublished - 1999

Fingerprint

von Willebrand Diseases
von Willebrand Factor
Bleeding Time
Deamino Arginine Vasopressin
Blood Platelets
Type 1 von Willebrand Disease
Type 2 von Willebrand Disease
Hemorrhage
Factor VIII
Therapeutics
Hemostasis

Keywords

  • Acquired von Willebrand syndrome
  • Congenital von Willebrand disease
  • Desmopressin
  • Factor VIII/von Willebrand factor concentrates
  • Von Willebrand factor

ASJC Scopus subject areas

  • Hematology

Cite this

Diagnosis and management of von Willebrand disease. / Federici, A. B.; Mannucci, P. M.

In: Haemophilia, Vol. 5, No. SUPPL. 2, 1999, p. 28-37.

Research output: Contribution to journalArticle

Federici, AB & Mannucci, PM 1999, 'Diagnosis and management of von Willebrand disease', Haemophilia, vol. 5, no. SUPPL. 2, pp. 28-37.
Federici, A. B. ; Mannucci, P. M. / Diagnosis and management of von Willebrand disease. In: Haemophilia. 1999 ; Vol. 5, No. SUPPL. 2. pp. 28-37.
@article{e2bb91edeb1e4c99afec4c3e5fcad46a,
title = "Diagnosis and management of von Willebrand disease",
abstract = "von Willebrand disease (vWD) is a bleeding disorder caused by quantitative or qualitative defects of von Willebrand factor (vWF). The diagnosis is based on measurements of plasma and platelet vWF, the ability of vWF to interact with its platelet receptor and the analysis of the mutlimeric composition of vWF. Due to the heterogeneity of vWF defects, a correct diagnosis of types and subtypes may be sometimes difficult but is very important for an appropriate therapy. The aim of treatment is to correct the dual defects of haemostasis, i.e. abnormal coagulation expressed by low levels of factor VIII (FVIII) and abnormal platelet adhesion expressed by a prolonged bleeding time (BT). Desmopressin is the treatment of choice in patients with type 1 vWD, who account for approximately 80{\%} of cases, because it corrects the FVIII/vWF levels and the prolonged BT in most of these patients. In type 3 and in the majority of type 2 vWD patients, desmopressin is not effective and it is necessary to resort to plasma concentrates containing FVIII and vWF. Treated with virucidal methods, these concentrates are effective and currently safe, but the BT defect is not always corrected by them. Platelet concentrates or desmopressin can be used as adjunctive treatments when poor correction of the BT after concentrates is associated with continued bleeding.",
keywords = "Acquired von Willebrand syndrome, Congenital von Willebrand disease, Desmopressin, Factor VIII/von Willebrand factor concentrates, Von Willebrand factor",
author = "Federici, {A. B.} and Mannucci, {P. M.}",
year = "1999",
language = "English",
volume = "5",
pages = "28--37",
journal = "Haemophilia",
issn = "1351-8216",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Diagnosis and management of von Willebrand disease

AU - Federici, A. B.

AU - Mannucci, P. M.

PY - 1999

Y1 - 1999

N2 - von Willebrand disease (vWD) is a bleeding disorder caused by quantitative or qualitative defects of von Willebrand factor (vWF). The diagnosis is based on measurements of plasma and platelet vWF, the ability of vWF to interact with its platelet receptor and the analysis of the mutlimeric composition of vWF. Due to the heterogeneity of vWF defects, a correct diagnosis of types and subtypes may be sometimes difficult but is very important for an appropriate therapy. The aim of treatment is to correct the dual defects of haemostasis, i.e. abnormal coagulation expressed by low levels of factor VIII (FVIII) and abnormal platelet adhesion expressed by a prolonged bleeding time (BT). Desmopressin is the treatment of choice in patients with type 1 vWD, who account for approximately 80% of cases, because it corrects the FVIII/vWF levels and the prolonged BT in most of these patients. In type 3 and in the majority of type 2 vWD patients, desmopressin is not effective and it is necessary to resort to plasma concentrates containing FVIII and vWF. Treated with virucidal methods, these concentrates are effective and currently safe, but the BT defect is not always corrected by them. Platelet concentrates or desmopressin can be used as adjunctive treatments when poor correction of the BT after concentrates is associated with continued bleeding.

AB - von Willebrand disease (vWD) is a bleeding disorder caused by quantitative or qualitative defects of von Willebrand factor (vWF). The diagnosis is based on measurements of plasma and platelet vWF, the ability of vWF to interact with its platelet receptor and the analysis of the mutlimeric composition of vWF. Due to the heterogeneity of vWF defects, a correct diagnosis of types and subtypes may be sometimes difficult but is very important for an appropriate therapy. The aim of treatment is to correct the dual defects of haemostasis, i.e. abnormal coagulation expressed by low levels of factor VIII (FVIII) and abnormal platelet adhesion expressed by a prolonged bleeding time (BT). Desmopressin is the treatment of choice in patients with type 1 vWD, who account for approximately 80% of cases, because it corrects the FVIII/vWF levels and the prolonged BT in most of these patients. In type 3 and in the majority of type 2 vWD patients, desmopressin is not effective and it is necessary to resort to plasma concentrates containing FVIII and vWF. Treated with virucidal methods, these concentrates are effective and currently safe, but the BT defect is not always corrected by them. Platelet concentrates or desmopressin can be used as adjunctive treatments when poor correction of the BT after concentrates is associated with continued bleeding.

KW - Acquired von Willebrand syndrome

KW - Congenital von Willebrand disease

KW - Desmopressin

KW - Factor VIII/von Willebrand factor concentrates

KW - Von Willebrand factor

UR - http://www.scopus.com/inward/record.url?scp=0032773359&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032773359&partnerID=8YFLogxK

M3 - Article

C2 - 23401897

AN - SCOPUS:0032773359

VL - 5

SP - 28

EP - 37

JO - Haemophilia

JF - Haemophilia

SN - 1351-8216

IS - SUPPL. 2

ER -